Viropharma Down 20% After FDA Approves Generic VANCOCIN

Viropharma VPHM is trading lower on the session following the announcement that the FDA has approved Watson Pharmaceuticals's WPI generic VANCOCIN. The capsules are for the treatment of C. difficile-associated diarrhea and also for the treatment of enterocolitis caused by Staphylococcus aureus. Viropharma is engaged in the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. The stock is down 18 year-to-date. The shares of Viropharma are currently trading at $22.65, a loss of $5.97 or 20.85%.